Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 30, 2014, 01:01:02 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 644039
  • Total Topics: 49019
  • Online Today: 193
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Isentress, just a nice story  (Read 818 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Isentress, just a nice story
« on: November 19, 2008, 12:35:10 PM »
Randy Gaston had few options left. The drugs were no longer helping him fight HIV.

So Gaston's doctor suggested he participate in a clinical trial in Palm Springs last year testing a new drug for patients who had become resistant to other HIV medications.

“Nothing seemed to work,” recalled Gaston of Cathedral City. “When this clinical trial came along, I jumped at it.”

A year after the federal Food and Drug Administration approved use of Isentress, patients such as Gaston and medical experts say it appears to work, improving the condition of some HIV patients and sparking hope that drug makers may develop similar medications.

The drug was hailed as an important new treatment for HIV patients. Isentress is the brand name of raltegravir, a drug made by New Jersey-based Merck & Co.

“It gives great promise in people whose virus is resistant to many of the other available drugs,” said Roy Steigbigel, a professor of medicine at Stony Brook University in New York who co-authored a report on raltegravir in the New England Journal of Medicine.

It takes about a year after a drug is available before people learn much about it, said Mark Milano, an HIV treatment educator at the AIDS Community Research Initiative of America in New York.

“If nothing serious has shown up in that year, that's a good thing,” said Milano, who has been using Isentress since December.

Unlike many HIV drugs, Isentress is taken orally only twice a day and tends to have fewer side effects. It has not been approved for first-time HIV medication users.

As part of the clinical trial, Gaston was on a combination of four drugs, including Isentress. Within 30 days, he said, his viral load level, the amount of HIV in his blood system, dropped from 100,000 to being undetectable.

“I was ready to go celebrate,” said Gaston, 46. “It was great.”

Gaston, who learned he was HIV positive in 1988, said he struggled for years to find the right combination of medicines. Now, he hopes to return to work teaching customers how to use ultrasound diagnostic medical equipment.

“It has done wonders for my mental status,” he said. “I'm hopeful that it will work for me long term, that I wouldn't have to change medication again.”

Nationally, nearly 450,000 people live with AIDS, according to the Kaiser Family Foundation. California, with 14 percent of the reported AIDS cases through 2006, ranks second to New York with 17.9 percent, according to Kaiser.

Rep. Mary Bono Mack, R-Palm Springs, and other advocates have pushed for more federal funding for research.

“Continued innovation in this field is especially critical in the desert where so many long-term survivors reside and are in need of additional treatment options,” she said.

For six months last year, the Desert AIDS Project in Palm Springs served as a clinical trial for Isentress in which patients were offered the drug along with other medications.

The group serves 2,300 HIV patients, offering housing assistance, medical care and other services. But officials estimate 7,500 people are living with HIV in the area, which has a growing gay population and attracts patients from San Francisco and as far as Ft. Lauderdale, Fla.

Geoff Zamboni, the project's director of medical services, said drugs such as Isentress offer patients “stabilization.”

“That's the best we can hope for right now with any drug,” he said.

Advocates hope drug companies will study Isentress and develop other drugs so HIV patients taking medications for the first time can use them.

“We do need the new class of drugs,” said Dr. Homayoon Khanlou, chief of medicine for the AIDS Healthcare Foundation, the nation's largest provider of medical care services. “There are not many newer agents in the pipeline.”

Like many HIV drugs, Isentress was on the FDA's fast track for approval. It took about six months. Advocates and lawmakers have pressed the FDA to speed up approval process.

“People are dying now,” said Milano, adding that safety studies continue after FDA approval. “If we wait five more years to get the drugs out, people will avoid the risks, but they will also be dead.”

The FDA had cautioned, however, that the long-term effect of Isentress is unknown and that its safety in children younger than 16 had not been studied. According to FDA officials, there are no reports of safety issues with the drug.

Milano started using Isentress in December after he was diagnosed with anal cancer and needed to get his viral load level down quickly. In three weeks, his viral load dropped from about 1 million to about 50.

“We just wanted that first drop and it did that,” said Milano, whose is in remission. “It's worked quite well for me.”

http://www.mydesert.com/apps/pbcs.dll/article?AID=2008811180314

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.